We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Griffin Mining, Energy XXI

Thu, 06th May 2010 12:49

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008.The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $25.4m from $32.1m.Griffin said it shut down Caijiaying in the first half the year, which enabled it to improve the mine's efficiency once it re-opened in the second half and metals prices had recovered.Bermuda-based oil group Energy XXI saw third quarter earnings before interest, taxes, depreciation, depletion and amortization rise by a third from the same period a year ago to $87.3m.'This quarter's results benefitted from our December consolidation of interests in our key Gulf of Mexico shelf properties and reflect the advantage of having an oil-focused production portfolio,' chairman and chief executive John Schiller said.Investors have welcomed news that respiratory disease drug developer Synairgen's inhaled interferon beta (IFN-beta) to treat rhinovirus infections in asthma and chronic obstructive pulmonary disease (COPD) has been granted in Europe."The European patent grant and the US patent granted last year are key ingredients in the out-licensing package," said chief executive Richard Marsden.Deltex Medical, whose Oesophageal Doppler monitoring equipment is used to measure blood flow in surgery patients, has received a forward order for probes worth at least $204,000 over the next six months. The disposable probes, used with Deltex's CardioQ-ODM system, are placed into the oesophagus through either the mouth or nose and help calculate how quickly blood is flowing. A reduction in circulating blood volume can be deadly.South Africa-focused ferrochrome producer International Ferro Metals, which has its head office in Sydney, thinks it will not be affected by Australia's proposals for a supertax on mining companies.'As all of IFL's operations and resources are located in South Africa with no mining activities undertaken in Australia, IFL believes, having consulted with its advisors, that it will not be liable for the newly proposed resource rent tax,' it says. Personnel software provider Allocate Software has bought Dynamic Change, a compliance and performance management software developer focused on the UK healthcare market. Allocate will pay up to £9m over three years for Dynamic Change, with £4.9m in cash and £0.1m in shares being paid upfront. The company is being acquired with cash balances and receivables of around £1.6m, largely reflecting deferred income which arises from subscriptions paid annually in advance. Clapham House, the restaurant group that owns the Gourmet Burger Kitchen (GBK) brand, is to raise £2.2m from a placing of 3.73m shares at 60p each. The funds will be used to accelerate the expansion of the GBK chain.Product development software specialist Sopheon has sealed 12 new and extension licence orders so far in 2010. Since the company's last trading update on 24 March revenue visibility for the full year from contracted business and recurring revenue streams has risen to £5.6m from £4.8m.
More News
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
26 May 2020 13:55

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
29 Mar 2020 21:00

Sunday share tips: Synairgen, Hollywood Bowl

(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.

Read more
29 Mar 2020 20:57

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times

Read more
26 Mar 2020 14:26

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

Read more
26 Mar 2020 06:58

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Read more
18 Mar 2020 18:42

Britain's Synairgen gets green light for coronavirus drug trial

By Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...

Read more
18 Mar 2020 16:59

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Read more
18 Mar 2020 11:17

Synairgen to begin trial of potential Covid-19 therapy

(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.

Read more
1 Oct 2019 13:42

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Read more
27 Sep 2019 13:32

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Read more
24 Jul 2019 12:58

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

Read more
9 Jul 2019 09:26

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

Read more
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.